Document Type: Original Articles


1 Professor, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran;

2 Professor, Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;

3 PhD Candidate, Student Research Committee, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran;

4 MSc, Student Research Committee, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran


Background: Use of glucosamine as an alternative treatment for osteoarthritis is becoming more frequent, including in those who have diabetes at the same time. The results from in vitro and animal studies propose that glucosamine may inversely affect glucose metabolism. However, the recommended dose of oral glucosamine in healthy people or diabetics did not have such effects consistently. The aim of the present study was to assess the effect of glucosamine on glycemic control and insulin resistance in type 2 diabetic patients. Methods: Fifty-four patients with type 2 diabetes participated in this randomized, double-blind, placebo-controlled study. The participants were assigned to receive 1500 mg glucosamine hydrochloride or placebo for 12 weeks. After determining their baseline characteristics, body mass index and dietary intake components, fasting blood glucose and fasting insulin were measured at weeks of 0, 8, and 12. Indices of insulin function including quantitative insulin sensitivity check index (QUICKI) and homeostasis model assessment of insulin resistance (HOMA-IR) were calculated by specific formulas. Independent t-test and general linear model repeated measures were used to analyze the data. Results: In the glucosamine group, the means of fasting blood glucose and insulin were 107.31±24.07 mg/dl and 8.75±4.37 μu/ ml, respectively at baseline, which reached 112.38±31.50 and 9.10±4.17 at week 12. In the placebo group, the mean for fasting blood glucose and insulin were 103.84±24.15 and 9.79±4.02 at the beginning of the study, which reached to 111.40±26.43 and 8.58±3.68 at week 12. The results showed that there were no significant differences in fasting blood glucose, insulin, HOMA-IR and QUICKI indices at all the studied time points (weeks of 0, 8 and 12) within or between the groups. Conclusion: Twelve weeks of a normal recommended dose of glucosamine supplements may not have adverse effects on glycemic control and insulin resistance in type 2 diabetic patients.Trial registration number: IRCT2014031811785N2.


  1. Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review
  2. on the role of antioxidants in the management of
  3. diabetes and its complications. Biomed Pharmacother
  4. ; 59(7): 365-73.
  5. Oh S, Kalyani RR, Dobs A. Nutritional management of
  6. diabetes mellitus. In: Ross AC, Caballero B, Cousins
  7. RJ, Tucker KL, Ziegler TR. Modern nutrition in health
  8. and disease. 11th ed. Philadelphia: Lippincott Williams
  9. & Wilkins; 2014.
  10. Gomez FE, Kaufer-Horwitz M. Medical nutrition
  11. therapy for rheumatic disease. In: Mahan LK, Escott-
  12. Stump S, Raymond J. Krause’s food and the nutrition
  13. care process. 13th ed. St. Louis, Mo: Elsevier/Saunders;
  14. Scroggie DA, Albright A, Harris MD. The effect
  15. of glucosamine-chondroitin supplementation on
  16. glycosylated hemoglobin levels in patients with type
  17. diabetes mellitus: a placebo-controlled, doubleblinded,
  18. randomized clinical trial. Arch Intern Med
  19. ; 163(13): 1587-90.
  20. Rahman N, Penm E, Bhatia K. Arthritis and
  21. musculoskeletal conditions in Australia 2005, with
  22. a focus on osteoarthritis, rheumatoid arthritis and
  23. osteoporosis/ Australian Institute of Health and
  24. Welfare. Canberra: 2005.
  25. Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine
  26. effects in humans: a review of effects on glucose
  27. metabolism, side effects, safety considerations and
  28. efficacy. Food Chem Toxicol 2005; 43(2): 187-201.
  29. Al-Saeed A. Gastrointestinal and cardiovascular risk
  30. of nonsteroidal anti-inflammatory drugs. Oman Med
  31. J 2011; 26(6): 385-91.
  32. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune
  33. E, Bruyere O, et al. Long-term effects of glucosamine
  34. sulphate on osteoarthritis progression: a randomised,
  35. placebo-controlled clinical trial. Lancet 2001;
  36. (9252): 251-6.
  37. Derfoul A, Miyoshi AD, Freeman DE, Tuan RS.
  38. Glucosamine promotes chondrogenic phenotype in
  39. both chondrocytes and mesenchymal stem cells and
  40. inhibits MMP-13 expression and matrix degradation.
  41. Osteoarthritis Cartilage 2007; 15(6): 646-55.
  42. Yu JG, Boies SM, Olefsky JM. The effect of oral
  43. glucosamine sulfate on insulin sensitivity in human
  44. subjects. Diabetes Care 2003; 26(6): 1941-2.
  45. Stumpf JL, Lin SW. Effect of glucosamine on glucose
  46. control. Ann Pharmacother 2006; 40(4): 694-8.
  47. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine
  48. supplementation on fasting and non-fasting plasma
  49. glucose and serum insulin concentrations in healthy
  50. individuals. Osteoarthritis Cartilage 2004; 12(6):
  51. -11.
  52. Nakaishi Y, Bando M, Shimizu H, Watanabe K,
  53. Goto F, Tsuge H, et al. Structural analysis of human
  54. glutamine:fructose-6-phosphate amidotransferase, a
  55. key regulator in type 2 diabetes. FEBS Lett 2009;
  56. (1): 163-7.
  57. Munoz N. Glucosamine reduces glycogen storage in L6
  58. skeletal muscle cells [MSc thesis]: Washington State
  59. University; 2007.
  60. Hawkins M, Hu M, Yu J, Eder H, Vuguin P, She L, et al.
  61. Discordant effects of glucosamine on insulin-stimulated
  62. glucose metabolism and phosphatidylinositol 3-kinase
  63. activity. J Biol Chem 1999; 274(44): 31312-9.
  64. Dostrovsky NR, Towheed TE, Hudson RW,
  65. Anastassiades TP. The effect of glucosamine on glucose
  66. metabolism in humans: a systematic review of the
  67. literature. Osteoarthritis Cartilage 2011; 19(4): 375-80.
  68. Albert SG, Oiknine RF, Parseghian S, Mooradian AD,
  69. Haas MJ, McPherson T. The effect of glucosamine on
  70. Serum HDL cholesterol and apolipoprotein AI levels
  71. in people with diabetes. Diabetes Care 2007; 30(11):
  72. -3.
  73. Namvaran F, Azarpira N, Rahimi-Moghaddam P,
  74. Dabbaghmanesh MH. Polymorphism of peroxisome
  75. proliferator-activated receptor γ (PPARγ) Pro12Ala in
  76. the Iranian population: relation with insulin resistance
  77. and response to treatment with pioglitazone in type 2
  78. diabetes. Eur J Pharmacol 2011; 671(1-3): 1-6.
  79. Pouwels MJ, Jacobs JR, Span PN, Lutterman JA, Smits
  80. P, Tack CJ. Short-term glucosamine infusion does not
  81. affect insulin sensitivity in humans. J Clin Endocrinol
  82. Metab 2001; 86(5): 2099-103.
  83. Monauni T, Zenti MG, Cretti A, Daniels MC, Targher
  84. G, Caruso B,et al. Effects of glucosamine infusion on
  85. insulin secretion and insulin action in humans. Diabetes
  86. ; 49(6): 926-35.
  87. Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon
  88. TE. Effects of oral glucosamine sulphate on serum
  89. glucose and insulin during an oral glucose tolerance
  90. test of subjects with osteoarthritis. Ann Rheum Dis
  91. ; 66(2): 260-2.
  92. Singh B, Saxena A. Surrogate markers of insulin
  93. resistance: A review. World J Diabetes 2010; 1(2): 36-47.